XNASSEER
Market cap145mUSD
Jan 06, Last price
2.45USD
1D
6.01%
1Q
23.50%
IPO
-95.95%
Name
Seer Inc
Chart & Performance
P/E
—
P/S
9.51
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
24.37%
Rev. gr., 5y
53.14%
Revenues
15m
+3.38%
Net income
-86m
L-2.73%
CFO
-59m
L-2.82%
Earnings
Feb 26, 2025
Profile
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 15,182 3.38% | 14,685 129.67% | ||||
Cost of revenue | 61,174 | 53,740 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (45,992) | (39,055) | ||||
NOPBT Margin | ||||||
Operating Taxes | (4,269) | |||||
Tax Rate | ||||||
NOPAT | (45,992) | (34,786) | ||||
Net income | (86,277) -2.73% | (88,697) 29.23% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (13) | 3,118 | ||||
BB yield | 0.01% | -0.86% | ||||
| Debt | ||||||
Debt current | 4,590 | 1,842 | ||||
Long-term debt | 54,223 | 57,906 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 179 | 320 | ||||
Net debt | (314,269) | (366,648) | ||||
| Cash flow | ||||||
Cash from operating activities | (59,065) | (60,780) | ||||
CAPEX | (7,309) | (10,265) | ||||
Cash from investing activities | 37,904 | (122,718) | ||||
Cash from financing activities | 452 | 3,893 | ||||
FCF | (50,108) | (50,969) | ||||
| Balance | ||||||
Cash | 316,224 | 421,239 | ||||
Long term investments | 56,858 | 5,157 | ||||
Excess cash | 372,323 | 425,662 | ||||
Stockholders' equity | (305,964) | (220,746) | ||||
Invested Capital | 733,601 | 697,598 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 63,850 | 62,434 | ||||
Price | 1.94 -66.55% | 5.80 -74.57% | ||||
Market cap | 123,870 -65.79% | 362,115 -73.92% | ||||
EV | (190,399) | (4,533) | ||||
EBITDA | (40,414) | (35,113) | ||||
EV/EBITDA | 4.71 | 0.13 | ||||
Interest | 327 | |||||
Interest/NOPBT | ||||||